Vicore Pharma Appoints Former GSK VP Rob Slack as Chief Scientific Officer
VCRE sits 22% above its 52-week low of $13.55.
Summary
Vicore Pharma has appointed Rob Slack, a seasoned scientific leader with over 20 years of experience from GSK and Galecto, as its new Chief Scientific Officer, signaling a strengthened focus on its respiratory and fibrotic disease pipeline.
Key Events · Executive and Board Changes · VCRE
-
New Chief Scientific Officer Appointed
Vicore Pharma appointed Rob Slack, PhD, FRSB, as its new Chief Scientific Officer, effective July 6, 2026.
-
Experienced Scientific Leader Joins
Dr. Slack brings over 20 years of drug discovery leadership, including roles as VP and Head of Respiratory Biology at GSK and acting CSO at Galecto, with a focus on fibrosis and respiratory translational science.
-
Smooth Leadership Transition
Former CSO, Dr. Johan Raud, will transition to a Senior Advisor role, ensuring continuity and support for upcoming milestones.
Analysis · VCRE · Life Sciences
This appointment strengthens Vicore Pharma's scientific leadership at a critical juncture for its clinical-stage pipeline. Dr. Slack's extensive background in respiratory and fibrotic disease drug discovery from GSK and Galecto is highly relevant to the company's focus on its lead program, buloxibutid, and expanding its next-generation pipeline. The smooth transition of the outgoing CSO to a Senior Advisor role also ensures continuity.
At the time of this filing, VCRE was trading at $16.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $390.1M. The 52-week trading range was $13.55 to $16.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.